MTOR and neoplasm: A hybrid capture-based next-generation sequencing of exons from 236 cancer-related genes in SCCA demonstrated the PI3K/AKT/mammalian target of rapamycin (MTOR) gene amplification and homozygous deletion in 63% of cases as well as PIK3CA as the most frequent tumor alteration in SCCA reported in 40% of patients [60].